945-24-4

Basic information

• Product Name: 2,4-DIAMINO-6-(HYDROXYMETHYL)PTERIDINE
• Synonyms: AKOS 213-118;(2,4-DIAMINO-PTERIDIN-6-YL)-METHANOL;(2,4-DIAMINO-6-PTERIDINYL)METHANOL;2,4-DIAMINO-6-PTERIDINEMETHANOL;2,4-DIAMINO-6-(HYDROXYMETHYL)PTERIDINE;2,4-diaminopteridine-6-ylmethanol;2,4-Diamino-6-hydroxymethylpteridine hydrochloride or HBR;2,4-DIAMINO-6-HYDROXYMETHYLPTERIDINE, 95 %
• CAS NO: 945-24-4
• Molecular Formula: C₇H₈N₆O
• Molecular Weight: 192.18
• EINECS: 213-412-2
• Product Categories: Benzhydrols, Benzyl & Special Alcohols;Heterocycles;Aromatics Compounds;Aromatics;Bases & Related Reagents;Inhibitors;Nucleotides
• Mol File: 945-24-4.mol
• Article Data: 17

Chemical Properties

• Melting Point: 333-334 °C (decomp)
• Boiling Point: 560.2 °C at 760 mmHg
• Flash Point: 292.6 °C
• Appearance: /
• Density: 1.673g/cm³
• Storage Temp.: 2-8°C
• PKA: 12.00±0.10(Predicted)
• CAS DataBase Reference: 2,4-DIAMINO-6-(HYDROXYMETHYL)PTERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DIAMINO-6-(HYDROXYMETHYL)PTERIDINE(945-24-4)
• EPA Substance Registry System: 2,4-DIAMINO-6-(HYDROXYMETHYL)PTERIDINE(945-24-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 945-24-4(Hazardous Substances Data)

Usage

Uses

2,4-Pteridinediamine-6-methanol (Methotrexate EP Impurity A) is an impurity of Methotrexate. A useful reagent for the development of selective antiparasitic compounds.

InChI:InChI=1/C7H8N6O/c8-5-4-6(13-7(9)12-5)10-1-3(2-14)11-4/h1,14H,2H2,(H4,8,9,10,12,13)

Upstream product

• 1004-74-6 2,4,5,6-tetraaminopyrimidine 
• 96-26-4 dihydroxyacetone 
• 39944-62-2 2,4,5,6-tetraamino-pyrimidine dihydrochloride 
• 5392-28-9 2,4,5,6-tetraaminopyrimidine sulfate 
• 10318-18-0 DL-cysteine hydrochloride 
• 191786-02-4 N-{2-Butyrylamino-6-[(E)-2-(4-ethyl-phenyl)-vinyl]-pteridin-4-yl}-butyramide 
• 191786-03-5 N-(2-Butyrylamino-6-formyl-pteridin-4-yl)-butyramide 
• 191786-01-3 β-(2,4-diamino-6-pteridinyl)-p-ethylstyrene 
• 52853-40-4 6-bromomethyl-2,4-diaminopteridine hydrobromide 
• 712-29-8 6-(hydroxymethyl)pterin 
• 52-89-1 l-cysteine hydrochloride 
• 522614-11-5 N-{[(acetyloxy)methyl]-4-[2-(4-nitrophenyl)ethoxy]pteridin-2-yl}acetamide 
• 59-05-2 N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid 
• 191786-04-6 N-(2-Butyrylamino-6-hydroxymethyl-pteridin-4-yl)-butyramide 

Downstream Products

• 19741-14-1 4-[(2,4-diaminopteridin-6-ylmethyl)methylamino]benzoic acid 
• 112113-77-6 N-<2-amino>benzoyl>-L-glutamic acid 
• 52853-40-4 6-bromomethyl-2,4-diaminopteridine hydrobromide 
• 57521-63-8 2,4-diamino-6-chloromethylpteridine 
• 23853-09-0 4-[(2,4-diaminopteridin-6-ylmethyl)-N-methylamino]benzoic acid methyl ester 
• 79640-70-3 (S)-5-(tert-butoxy)-4-(4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)-5-oxopentanoic acid 
• 54-62-6 aminopterin 
• 95484-99-4 α-methyl γ-tert-butyl N-(4-amino-4-deoxy-N¹⁰-formylpteroyl)-L-glutamate 
• 95485-00-0 γ-tert-butyl N-(4-amino-4-deoxy-N¹⁰-formylpteroyl)-L-glutamate 
• 95484-98-3 γ-tert-butyl N-(4-amino-4-deoxypteroyl)-L-glutamate 
• 95485-01-1 p-nitrophenyl 4-amino-4-deoxy-N¹⁰-formylpteroate 
• 79640-68-9 α-methyl γ-tert-butyl N-(4-amino-4-deoxy-N¹⁰-methylpteroyl)-L-glutamate 
• 79640-76-9 γ-tert-butyl N-(4-amino-4-deoxy-N¹⁰-methylpteroyl)-L-glutamate 
• 89043-75-4 4-amino-4-deoxy-N¹⁰-formylpteroic acid 

Relevant articles and documents

ANTIFOLATE-CARRYING NANOPARTICLES AND THEIR USE IN MEDICINE

The present invention provides a nanoparticle comprising: a core comprising a metal and/or a semiconductor; and a plurality of ligands covalently linked to the core, wherein said ligands comprise: (i) at least one dilution ligand comprising a carbohydrate, glutathione or an ethylene glycol-containing moiety; and (ii) a ligand of the formula D-L1-Z-L2, wherein D comprises an antifolate drug or folic acid, L1 comprises a first linker portion comprising a C2-C12 glycol and/or C2-C12 alkyl chain, L2 comprises a second linker portion comprising a C2-C12 glycol and/or C2-C12 alkyl chain, wherein L1 and L2 may be the same or different, and wherein Z represents a carbonyl-containing group linking L1 and L2, and wherein L2 is coupled to said core, Also provided are pharmaceutical compositions comprising such nanoparticles, medical uses thereof and methods for producing the nanoparticles.

PRODRUGS ACTIVATED BY REACTIVE OXYGEN SPECIES FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES AND CANCER

Prodrugs activated predominantly or exclusively in inflammatory tissue, more particularly prodrugs of methotrexate and derivatives thereof, which are selectively activated by Reactive Oxygen Species (ROS) in inflammatory tissues associated with cancer and inflammatory diseases, as well as method for preparing said prodrugs.

DIAMINOPTERIDINE DERIVATIVES

The present invention relates novel diaminopteridine derivatives, their compositions and method of treatment comprising the same for use as anti-infectives.